Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis

Dermatology

Volumn 204, Issue 1, 2002, Pages 63-68

  Van Leent, Edwin J M ^a   Ebelin, Marie Eve ^b   Burtin, Pascale ^b   Dorobek, Birgit ^b   Spuls, Phyllis I ^a   Bos, Jan D ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Atopic dermatitis; Elidel; Pharmacokinetics; Pimecrolimus; SDZ ASM 981

Indexed keywords

PIMECROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG REEXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; BIOLOGICAL AVAILABILITY; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 0036169163     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051813     Document Type: Article

References (15)

1. Management of atopic dermatitis
2. Pathogenesis of atopic eczema
3. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis
4. Tacrolimus ointment for atopic dermatitis
5. A short-term trial of tacrolimus ointment for atopic dermatitis
6. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology
7. A novel anti-inflammatory drug. SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
8. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981
9. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
10. Diagnostic features of atopic dermatitis
11. Severity scoring of atopic dermatitis: The SCORAD index
12. Standardized grading of subjects for clinical research studies in atopic dermatitis: Workshop report
13. Pilot studies on local and systemic side effects of SDZ ASM 981 in laboratory animals
14. Profiling SDZ ASM 981: Evaluation of local tolerability and safety in the treatment of atopic dermatitis
15. Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatitis lesions